CDMOs in China
29 published
29 published CDMOs match China.
Locations in this set include China, United States, Switzerland, France, Japan, and Singapore.
Capabilities that show up most often in this set: CMC Analytical Development, Process Development, CMC Regulatory Submission Support, Technology Transfer, and Formulation Development.
Matching companies
ProBioProBio is a leading global CDMO subsidiary of GenScript Biotech Corporation, providing end-to-end services for biologics and cell & gene therapy (CGT) from drug discovery through commercialization.
Roquette Pharma SolutionsRoquette is a leading global provider of plant-based ingredients, excipients, and solutions for the pharmaceutical and healthcare industries.
Stevanato GroupLeading global provider of integrated drug containment, drug delivery, and diagnostic solutions with 75+ years' experience in glass primary packaging, contract manufacturing, and analytical services across development, clinical, and commercial stages.
Unither PharmaceuticalsGlobal CDMO specializing in sterile and non-sterile liquid manufacturing, including Blow-Fill-Seal (BFS) single-dose technology with over 5 billion annual capacity, plus formulation development, analytical services, and ophthalmic expertise across six production sites.
Vetter PharmaIndependent CDMO specialist in aseptic fill-finish, drug product development, analytical services, and combination product assembly with 76 years of experience and 7,300+ employees globally.
WuXi VaccinesGlobal CDMO specializing in end-to-end vaccine and prophylactic antibody development and manufacturing across mammalian, viral, and microbial platforms with GMP-certified facilities and over 550 million doses delivered.
WuXi XDCWuXi XDC is a leading CRDMO offering integrated discovery, development, and cGMP manufacturing services for antibody drug conjugates (ADCs) and bioconjugates, with proximately located facilities that reduce development timelines and costs.
Yongtai TechnologyYongtai Technology is a chemical manufacturing and contract services provider based in Linhai, Zhejiang, operating pharmaceutical, agrochemical, and materials business divisions with capabilities in API synthesis and chemical manufacturing.- 重庆兴泰濠制药有限公司 (Sintaho)China-based API and CDMO/CMO supplier focused on cytotoxic and OEB5 high-potency APIs, peptides, and XDC compounds. Reports FDA on-site inspections in 2024 and 2025 and product registrations in more than 30 countries.
Markdown mirror: /countries/china.md